Company Overview of Chimerix, Inc.
Chimerix, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral antivirals in the areas of unmet medical needs in the United States. The company’s lead product candidate is brincidofovir (CMX001), a nucleotide analog, which is in Phase III clinical trials for the prevention of cytomegalovirus (CMV) in allogeneic hematopoietic cell transplant (HCT) recipients and in kidney transplant recipients, as well as to treat adenovirus infection in allogeneic HCT patients. It is also developing CMX157, a nucleotide analog that is in Phase II clinical stage for the treatment of HIV and hepatitis B virus infection. The company’s preclinical testing product comprises CMX669, a co...
2505 Meridian Parkway
Durham, NC 27713
Founded in 2000
Key Executives for Chimerix, Inc.
Chief Executive Officer, President and Director
Total Annual Compensation: $505.7K
Chief Financial Officer, Senior Vice President and Corporate Secretary
Total Annual Compensation: $332.5K
Chief Medical Officer
Total Annual Compensation: $493.0K
Chief Commercial Officer
Total Annual Compensation: $350.0K
Compensation as of Fiscal Year 2015.
Chimerix, Inc. Key Developments
Chimerix, Inc. Presents at The 2016 Morgan Stanley Global Healthcare Conference, Sep-12-2016 04:15 PM
Aug 18 16
Chimerix, Inc. Presents at The 2016 Morgan Stanley Global Healthcare Conference, Sep-12-2016 04:15 PM. Venue: The Grand Hyatt Hotel, New York, New York, United States. Speakers: M. Michelle Berrey, Chief Executive Officer, President and Director.
Chimerix, Inc. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2016
Aug 8 16
Chimerix, Inc. announced unaudited consolidated earnings results for the second quarter and six months ended June 30, 2016. For the quarter, the company reported net loss decreased to $18.1 million or $0.39 per basic and diluted share compared to a net loss of $24.8 million or $0.59 per basic and diluted share a year ago. Revenues decreased to $1.8 million compared to $4.1 million a year ago. Loss from operations was $18.5 million compared to a loss from operations of $25.0 million for a year ago. The decreased loss was primarily due to lower research and development expenses, and general and administrative expenses.
For the six months, the company reported revenues of $3.069 million against $5.381 million a year ago. Net loss was $44.408 million or $0.96 per basic and diluted share against $47.080 million or $1.13 per basic and diluted share a year ago. Loss from operations was $45.157 million against $47.279 million a year ago.
Chimerix, Inc. to Report Q2, 2016 Results on Aug 08, 2016
Aug 1 16
Chimerix, Inc. announced that they will report Q2, 2016 results at 12:00 PM, GMT Standard Time on Aug 08, 2016
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|